Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases
Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all mature B lymphocytes, including CLL cells. The...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institute of Oncology, Sremska Kamenica, Serbia
2009-01-01
|
| Series: | Archive of Oncology |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0354-7310/2009/0354-73100904065P.pdf |
| _version_ | 1818788274979733504 |
|---|---|
| author | Pejčić Ivica Vrbić Svetislav |
| author_facet | Pejčić Ivica Vrbić Svetislav |
| author_sort | Pejčić Ivica |
| collection | DOAJ |
| description | Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all mature B lymphocytes, including CLL cells. The CD20 receptors, characteristic for 'B' lymphoproliferative diseases, have been demonstrated to be a good target for therapeutic effects to be achieved. Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody, with the sequences of the human constant region and sequences of the murine variable region. It is specifically bound to the B-lymphocyte CD20 antigen. The mechanism of all rituximab antitumor activity has not been established, but ADCC and CDC are believed to be the principal, with possible complementary effects. Therapeutic use of anti-CD20 monoclonal antibodies has demonstrated a significant benefit in the patients with 'B' CD20 positive lymphoproliferative diseases. Rituximab is today a golden standard for the comparation with other treatment modalities, increasingly in combination with chemotherapy. |
| first_indexed | 2024-12-18T14:21:04Z |
| format | Article |
| id | doaj.art-eef71b2409a84257b992c2c5b9f07ec5 |
| institution | Directory Open Access Journal |
| issn | 0354-7310 |
| language | English |
| last_indexed | 2024-12-18T14:21:04Z |
| publishDate | 2009-01-01 |
| publisher | Institute of Oncology, Sremska Kamenica, Serbia |
| record_format | Article |
| series | Archive of Oncology |
| spelling | doaj.art-eef71b2409a84257b992c2c5b9f07ec52022-12-21T21:04:52ZengInstitute of Oncology, Sremska Kamenica, SerbiaArchive of Oncology0354-73102009-01-01173-4656710.2298/AOO0904065PApplication of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseasesPejčić IvicaVrbić SvetislavOut of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all mature B lymphocytes, including CLL cells. The CD20 receptors, characteristic for 'B' lymphoproliferative diseases, have been demonstrated to be a good target for therapeutic effects to be achieved. Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody, with the sequences of the human constant region and sequences of the murine variable region. It is specifically bound to the B-lymphocyte CD20 antigen. The mechanism of all rituximab antitumor activity has not been established, but ADCC and CDC are believed to be the principal, with possible complementary effects. Therapeutic use of anti-CD20 monoclonal antibodies has demonstrated a significant benefit in the patients with 'B' CD20 positive lymphoproliferative diseases. Rituximab is today a golden standard for the comparation with other treatment modalities, increasingly in combination with chemotherapy.http://www.doiserbia.nb.rs/img/doi/0354-7310/2009/0354-73100904065P.pdfLymphoproliferative DisordersAntibodiesMonoclonalAntigensCD20 |
| spellingShingle | Pejčić Ivica Vrbić Svetislav Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases Archive of Oncology Lymphoproliferative Disorders Antibodies Monoclonal Antigens CD20 |
| title | Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases |
| title_full | Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases |
| title_fullStr | Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases |
| title_full_unstemmed | Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases |
| title_short | Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases |
| title_sort | application of anti cd20 monoclonal antibodies in the treatment of lymphoproliferative diseases |
| topic | Lymphoproliferative Disorders Antibodies Monoclonal Antigens CD20 |
| url | http://www.doiserbia.nb.rs/img/doi/0354-7310/2009/0354-73100904065P.pdf |
| work_keys_str_mv | AT pejcicivica applicationofanticd20monoclonalantibodiesinthetreatmentoflymphoproliferativediseases AT vrbicsvetislav applicationofanticd20monoclonalantibodiesinthetreatmentoflymphoproliferativediseases |